1 / 25

ART. Switching for toxicity : how and when to switch ? Case Discussion

ART. Switching for toxicity : how and when to switch ? Case Discussion. Luis Soto-Ramírez, MD Head Molecular Virology Unit Department of Infectious Diseases Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran México City, MEXICO.

vivian-payne
Download Presentation

ART. Switching for toxicity : how and when to switch ? Case Discussion

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ART. Switchingfortoxicity: how and whentoswitch? Case Discussion Luis Soto-Ramírez, MD Head Molecular Virology Unit Department of Infectious Diseases Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran México City, MEXICO

  2. Male 31 years old, MSM referred to you to evaluate treatment switch. Smokes 1 pack a day, for the last 10 years. Weight 93 kg (BMI 29), sedentary. Blood Pressure: 120/85 . FH: Father died at 56 due to MI, had DM type 2. PMH: Diagnosed as HIV in March 2005 No OI, no co-infections (hep B-C) Case JMDA.

  3. Case: JMDA ARV treatmenthistory

  4. Isthis a perfect ART response? Yes No Itdepends – I need more information Case JMDA. Question 1

  5. SGPT / ALT: 81 IU/L (13 – 40) SGOT / AST : 41 IU/L (15 – 48) Triglycerides: 8.67 mmol/l (768 mg/dl). Total Cholesterol: 4.18 mmol/l (162 mg/dl). HDL: 0.620 mmol/l (24 mg/dl). Glucose: 5.44 mmol/l (94 mg/dl). Case JDMA. Otherlabs.

  6. Framingham Risk.

  7. What would you do? Treat with fibrate Diet, exercise and quit smoking Both Case JMDA. Question 2

  8. The patient decrease smoking to half a pack/day, but stopped the fibrate due to severe muscle cramps. Six months thereafter, had lost 4 kg, use Omega 3; his viral load is still undetectable and his lipids are: Triglycerides: 9.50 mmol/l (842 mg/dl). Total Cholesterol: 3.90 mmol/l ( 151 mg/dl). HDL: 0.80 mmol/l (31-mg/dl). Case JDMA. Follow up.

  9. Framingham Risk.

  10. He isnotwillingtostart a fibrateagain. ShouldweconsidertheTG important? Yes No Depends Case JMDA. Question 3

  11. Factors associated with mortality in HIV infected patients with metabolic syndrome

  12. Wouldyouswitchtreatmenttodecrease TG and CV risk? Yes No Case JMDA. Question4

  13. Retrospective, age-matched study of HIV+ and HIV- veterans with dyslipidemia BL TC or TGs > 200 mg/dL On lipid-lowering therapy > 2 months HIV+ subjects on HAART HIV+ subjects less frequently met NCEP goals after 6 months of treatment for dyslipidemia HIV+ subjects may not be receiving optimal care for dyslipidemia 85% of HIV- received simvastatin vs 23% of HIV+ Difference in usage likely due to interactions b/w simvastatin and PIs HIV+ HIV- Respond to lipid-lowering agents in HIV infected individuals 100 P = .033 80 P = .014 64 60 58 60 Patients Achieving NCEP Goal at 6 Months (%) 43 40 28 25 20 11 11 0 TC TG LDL HDL • Hollowell S, et al. ICAAC 2005. Abstract H-338.

  14. Switch Pis to NNRTIs vs lipid lowering agents • Colesterol total a los 12 meses

  15. Would you switch? Backbone Third agent Both Case JMDA. Question 5

  16. Would you do with the backbone? Continue ABC/3TC Change to TDF/FTC Other Case JMDA. Question6

  17. LIPID CHANGES WITH ARV TREATMENT *Effects shown are for ritonavir-boosted drugs †Atazanavir not licensed for unboosted use in the UK or EU Adapted from: 1. Martin A and Emery S. Exp Rev Clin Pharmacol 2009;2:381–389; 2. Fautkenheuer G, et al. J Antimicrob Chemother 2012;67:685–690; 3. Cohen C, et al. Lancet 2011;378:229–237; 4. Mills AM, et al. AIDS 2009;23:1679–1688

  18. LipidEffects of PIs Thistablerepresentstheauthor’s judgmentabouttherelativelipideffects of theagentslisted, basedonaccumulated data fromstudiesto date. Differentstudieshavereportedvaryinglipideffects, probablyinfluencedbystage of HIV infection, geographicrepresentation, and othercross-studydifferences. As a result, some individual studiesmayseeminconsistentwiththe ratings in thetable; nevertheless, thistablerepresentstheauthor’s bestattempttoreconcilealltheavailable data. Slide courtesy of Stefan Mauss, MD

  19. Wouldyou do switchthethirdagentto? Nevirapine PI/r Raltegravir Maraviroc Case JMDA. Question 7

  20. SPIRAL Study: Change (mean) in FastingLipidsthoughWeek 48. Martinez E. et al. AIDS 2010; 24: 1697-1707

  21. The patient was switched to TVD/Raltegravir. According to SPIRAL the changes in lipids would be: Case JDMA. Follow up.

  22. Switch strategies for virologically suppressed patients(confirmed plasma viral load < 50 c/mL) • Indications: • 1. Switch for toxicity • 2. Switch for prevention of long-term toxicity • 3. Switch for simplification • Principles: • 1. A boosted PI may be switched for simplification, prevention or improvement of metabolic abnormalities or adherence facilitation to unboosted atazanavir, an NNRTI or raltegravir only if full activity of the 2 NRTIs remaining is guaranteed. • 2. Simplification of a complex multidrug regimen in antiretroviral-experienced patients with 1) substitution of drugs difficult to administer (enfuvirtide) and/or with poor activity (NRTI in case of multiple NRTI resistance) and/or poor tolerability and 2) addition of new well-tolerable, simpler and active agent(s). • 3. Bid to qd NRTI switch for simplification, prevention of long-term toxicity. • 4. Intra-class switch if drug-specific related adverse event. • 5. Review the complete ARV history and available resistance test results. • 6. Avoid switching to a drug with a low genetic barrier in the presence of a backbone compromised by the possibility of archived class resistance.

  23. Conclusions • The importance of TG elevations in HIV+ individuals should be determined • Switches can be good specially in the long run, but are not the complete solution for dislypidemia • Specific switch guidelines should be created • For dyslipidemia and CV risk • For other metabolic complications • For kidney damage • For bone disease

  24. THANK YOU Terima kasih banyak GRACIAS

More Related